BC Week In Review | Oct 9, 2006
Clinical News

INNO-105: Development discontinued

Innovive discontinued development of INNO-105 based on results from a Phase I trial. The company said INNO-105 was unlikely to have desired plasma levels without causing adverse side effects. Innovive Pharmaceuticals Inc. , New York, N.Y....
BC Week In Review | Dec 5, 2005
Clinical News

INNO-105: Phase I started

Innovive started a dose-escalation, open-label, U.S. Phase I trial in 24 patients. Innovive Pharmaceuticals Inc. , New York, N.Y.   Product: INNO-105   Business: Cancer   Molecular target: Opioid growth factor receptor (OGFR)   Description: Naturally...
BC Week In Review | Oct 10, 2005
Clinical News

INNO-105: Start Phase I

Innovive will begin this quarter a dose-escalation, U.S. Phase I trial in 24 patients. Innovive Pharmaceuticals Inc. , New York, N.Y.   Product: INNO-105   Business: Cancer   Molecular target: Opioid growth factor receptor (OGFR)  ...
Items per page:
1 - 3 of 3